<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03926624</url>
  </required_header>
  <id_info>
    <org_study_id>D18-11141</org_study_id>
    <nct_id>NCT03926624</nct_id>
  </id_info>
  <brief_title>Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage</brief_title>
  <official_title>Phase 3 Randomized Trial of DFP-10917 vs Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High &amp; Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second, Third, or Fourth Salvage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Delta-Fly Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Delta-Fly Pharma, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase III, multicenter, randomized study with two arms (1:1 ratio) enrolling patients with&#xD;
      AML relapsed/refractory after 2, 3, or 4 prior induction regimens:&#xD;
&#xD;
      Experimental arm: DFP-10917 14-day continuous intravenous (IV) infusion at a dose of 6&#xD;
      mg/m²/day followed by a 14-day resting period per 28-day cycles.&#xD;
&#xD;
      Control arm: Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax&#xD;
      Combination Regimens) or Intensive Reinduction (High and Intermediate Dose Cytarabine&#xD;
      Regimens), depending on the patient's prior induction treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study to compare the rate of complete response (CR) and duration of CR, in patients with&#xD;
      relapsed or refractory AML to two, three, or four prior induction regimens that may have&#xD;
      included intensive chemotherapy (e.g., &quot;7+3&quot; cytarabine and daunorubicin), epigenetic therapy&#xD;
      (i.e., azacitidine or decitabine), or targeted therapy (e.g., FLT-3, IDH-1/2, BCL-2,&#xD;
      monoclonal antibody), who will receive DFP-10917 versus non-intensive reinduction (LoDAC,&#xD;
      azacitidine, decitabine, venetoclax + LoDAC or azacitidine or decitabine) or intensive&#xD;
      reinduction (high and intermediate dose cytarabine regimens) as a second, third, or fourth&#xD;
      salvage treatment.&#xD;
&#xD;
      Experimental Arm DFP-10917 Dose: 6 mg/m²/day administered by continuous infusion for 14 days&#xD;
      followed by a 14-day resting period per 28-day treatment cycle. If a patient experiences a&#xD;
      significant treatment-related AE, the patient may undergo one dose reduction of DFP-10917 to&#xD;
      4 mg/m²/day x 14 days for subsequent treatment cycles&#xD;
&#xD;
      Control arm: Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax + LoDAC or&#xD;
      Azacitidine or Decitabine) or Intensive Reinduction (High and Intermediate Dose Cytarabine&#xD;
      Regimens), depending on the patient's prior induction treatment as well as the patient's&#xD;
      clinical condition and comorbidities. Control treatment is to be selected only from among the&#xD;
      following. Institutional practice for administering these treatments are permitted, but the&#xD;
      dose and days of drug administration should be followed as below.&#xD;
&#xD;
      Non-Intensive Reinduction:&#xD;
&#xD;
        -  LoDAC: 20 mg Cytarabine administered by subcutaneous (SC) injection, twice daily (BID)&#xD;
           for 10 days, plus best supportive care per 28-day treatment cycle&#xD;
&#xD;
        -  Azacitidine: 75 mg/m²/day administered by SC for 7 consecutive days (or 5+2), plus best&#xD;
           supportive care per 28-day treatment cycle&#xD;
&#xD;
        -  Decitabine: administered as continuous intravenous (CIV) infusion 20 mg/m² x 5 days plus&#xD;
           best supportive care per 28 day treatment cycle&#xD;
&#xD;
        -  Venetoclax + LoDAC or Azacitidine or Decitabine: In combination with LoDAC, Venetoclax&#xD;
           will be administered via a daily ramp-up to a final 600 mg once daily dose. During the&#xD;
           ramp-up, patients are to receive TLS prophylaxis and may be hospitalized for monitoring.&#xD;
           Cytarabine will be administered subcutaneously at a dose of 20 mg/m² once daily on Days&#xD;
           1-10 of each 28-day cycle beginning Cycle 1 Day 1. In combination with Azacitidine or&#xD;
           Decitabine, Venetoclax will be administered via a daily ramp-up to a final 400 mg once&#xD;
           daily dose. Azacitidine will be administered intravenously or subcutaneously at a dose&#xD;
           of 75 mg/m² on Days 1-7 of each 28-day cycle beginning on Cycle 1 Day 1. Decitabine will&#xD;
           be administered via IV at a dose of 20 mg/m² on Days 1-5 or 1-10, as per institutional&#xD;
           practice, of each 28-day cycle beginning Cycle 1 Day 1.&#xD;
&#xD;
      Intensive Reinduction:&#xD;
&#xD;
        -  High DAC = cytarabine at doses of 1-2 g/m²/day for up to 5 days, with a maximum total&#xD;
           dose 10 g/m² per course&#xD;
&#xD;
        -  FLAG = Days 1-5: fludarabine 30 mg/m² IV over 30 minutes, Days 1-5: cytarabine 1 2&#xD;
           grm/m² over 4 hours daily x 5, and granulocyte colony-stimulating factor 5 mcg/kg or 300&#xD;
           mcg/m² until Polymorphonuclear Neutrophil (PMN) recovery, with or without idarubicin&#xD;
           Days 1-3 at 8 mg/m² IV daily x 3 (FLAG-Ida)&#xD;
&#xD;
        -  MEC = Days 1-6: mitoxantrone 6 mg/m² IV bolus, etoposide 80 mg/m² IV over 1 hour, and&#xD;
           cytarabine 1 grm/m² IV over 6 hrs (Etoposide may be deleted per institutional&#xD;
           guidelines, i.e., HAM regimen)&#xD;
&#xD;
        -  CLAG/M or Ida = cladribine 5 mg/m² on Days 1-5, cytarabine 2 g/m² on Days 1-5,&#xD;
           granulocyte-colony stimulating factor 300 μg on Days 0-5 (G-CSF starts 24 hr prior to&#xD;
           chemotherapy), and mitoxantrone 10 mg/m² on Days 1-3 or Idarubicin 10 mg/m² on Days 1-3&#xD;
&#xD;
        -  Intermediate DAC = cytarabine 20 mg/m² IV daily x 5&#xD;
&#xD;
      The selection of control arm treatment will be determined by the investigator depending on&#xD;
      the patient's prior initial induction and salvage treatment regimen(s), as well as the&#xD;
      patient's clinical condition and comorbidities. The investigator will select the patient's&#xD;
      control treatment from among the non-intensive or intensive regimens prior to study treatment&#xD;
      randomization in order to balance treatment allocation between the experimental and control&#xD;
      treatment arms.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 22, 2019</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized, controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete remission (CR) rate</measure>
    <time_frame>3 years</time_frame>
    <description>The rate of CR based on International Working Group (IWG) Guidelines for bone marrow and blood response</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of complete remission</measure>
    <time_frame>3 years</time_frame>
    <description>Number of days from time of initial CR until disease recurrence or death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The rate of complete remission (CR) + (complete remission with incomplete hematologic recovery) CRi+ (complete remission with partial hematologic recovery) CRp</measure>
    <time_frame>3 years</time_frame>
    <description>CR as above including neutrophil granulocyte count &gt; 0.5x10^9/L &amp; platelet count &gt; 50x10^9/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The duration of complete remission (CR) + (complete remission with incomplete hematologic recovery) CRi+ (complete remission with partial hematologic recovery) CRp</measure>
    <time_frame>3 years</time_frame>
    <description>CR as above including neutrophil granulocyte count &gt; 0.5x10^9/L &amp; platelet count &gt; 50x10^9/L + platelet count &lt; 100x10^9/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
    <description>Number of days from date of first dose to date of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transition rate to hematopoietic stem cell transplantation (HSCT)</measure>
    <time_frame>3 years</time_frame>
    <description>Number of subjects who transition to HSCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>3 years</time_frame>
    <description>The rate of CR + CRi + CRp + PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration overall response</measure>
    <time_frame>3 years</time_frame>
    <description>The duration of CR + CRi + CRp + PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of disease related co-morbidities</measure>
    <time_frame>3 years</time_frame>
    <description>Number and severity of expected leukemia-related adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>3 years</time_frame>
    <description>Number of patients with adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Leukemia, Myeloid, Acute</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DFP-10917 Dose: 6 mg/m²/day administered by continuous infusion for 14 days followed by a 14-day resting period per 28-day treatment cycle. If a patient experiences a significant treatment-related AE, the patient may undergo one dose reduction of DFP-10917 to 4 mg/m²/day x 14 days for subsequent treatment cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Non-Intensive:&#xD;
LoDAC: 20 mg SC BID 10 days&#xD;
Azacitidine: 75 mg/m²/day SC 7 days(or 5+2)&#xD;
Decitabine: CIV 20 mg/m²x5 days&#xD;
Venetoclax + LoDAC/Azacitidine/Decitabine:LoDAC-Venetoclax ramp-up to 600 mgxday. Cytarabine SC 20 mg/m²xday D1-10. Azacitidine or Decitabine-Venetoclax ramp-up to 400 mgxday. Azacitidine IV or SC 75 mg/m² D1-7. Decitabine IV 20 mg/m² on D1-5 or 1-10.&#xD;
Intensive:&#xD;
High DAC: cytarabine 1-2 g/m² up to 5 days, max total dose 10 g/m²&#xD;
FLAG: D1-5: fludarabine 30 mg/m² IV for 30min, D1-5: cytarabine 1-2 g/m² for 4hr daily x 5 &amp; G-CSF 5 mcg/kg or 300 mcg/m² until PMN recovery, with or without idarubicin D1-3 8 mg/m² IV dailyx3 (FLAG-Ida)&#xD;
MEC: D1-6: mitoxantrone 6 mg/m² IV bolus, etoposide 80 mg/m² IV 1hr &amp; cytarabine 1g/m² IV 6hr.&#xD;
CLAG/M or Ida = cladribine 5 mg/m² D1-5, cytarabine 2 g/m² D1-5, G-CSF 300 μg D0-5, mitoxantrone 10 mg/m² D1-3 or Idarubicin 10 mg/m² D1-3.&#xD;
Intermediate DAC: cytarabine 20 mg/m² IV dailyx5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DFP-10917</intervention_name>
    <description>DFP-10917 Powder for Injection. Active ingredient: 4-amino-1-(2-cyano-deoxy-β-D-arabinofuranosyl)-2(1H)-pyrimidinone monohydrochloride</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>cytosine arabinoside (ara-C)</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>Azacitidine</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Decitabine</intervention_name>
    <description>Decitabine</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitoxantrone</intervention_name>
    <description>Mitoxantrone</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Etoposide</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Fludarabine</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idarubicin</intervention_name>
    <description>Idarubicin</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>Venetoclax</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cladribine</intervention_name>
    <description>Cladribine</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically or pathologically confirmed diagnosis of AML based on WHO&#xD;
             classification that has relapsed after, or is refractory to, two, three, or four prior&#xD;
             induction regimens that may have included intensive chemotherapy (e.g., &quot;7+3&quot;&#xD;
             cytarabine and daunorubicin), epigenetic therapy (i.e., azacitidine or decitabine), or&#xD;
             targeted therapy (e.g., FLT-3, IDH-1/2, BCL-2, monoclonal antibody).&#xD;
&#xD;
             (Relapse is defined as reemergence of ≥5% leukemia blasts in bone marrow or ≥1% blasts&#xD;
             in peripheral blood ≥90 days after first CR or CR without complete platelet recovery&#xD;
             (CRp). Refractory AML is defined as persistent disease ≥28 days after initiation of&#xD;
             intensive induction therapy (up to two induction cycles) or relapse &lt;90 days after&#xD;
             first CR or CRp. Refractory disease for patients undergoing hypomethylating agent&#xD;
             induction is defined as lack of remission following at least 2 cycles of epigenetic&#xD;
             therapy without reduction in bone marrow blast status.)&#xD;
&#xD;
             Patients with a history of IPSS-R high or very high risk MDS that transformed to AML&#xD;
             during treatment with hypomethylating drugs and then relapse following or are&#xD;
             refractory to a subsequent AML induction regimen may be enrolled as Second Salvage AML&#xD;
             patients. Additionally, patients with a history of MPN in accelerated phase (MPN-AP)&#xD;
             or high-risk primary myelofibrosis (PMF) that transformed to AML during treatment with&#xD;
             hypomethylating drugs and then relapse following or are refractory to a subsequent AML&#xD;
             induction regimen may be enrolled as Second Salvage AML patients.&#xD;
&#xD;
          2. Aged ≥ 18 years.&#xD;
&#xD;
          3. ECOG Performance Status of 0, 1 or 2.&#xD;
&#xD;
          4. Adequate clinical laboratory values (i.e., plasma creatinine &lt;2.5 x upper limit of&#xD;
             normal (ULN) for the institution, bilirubin &lt;2.5 x ULN, alanine transaminase (ALT) and&#xD;
             aspartate transaminase (AST) ≤2.5 x ULN).&#xD;
&#xD;
          5. Absence of active central nervous system (CNS) involvement by leukemia. Patients with&#xD;
             previously diagnosed CNS leukemia are eligible if the CNS leukemia is under control&#xD;
             and intrathecal treatment may continue throughout the study.&#xD;
&#xD;
          6. Absence of uncontrolled intercurrent illnesses, including uncontrolled infections,&#xD;
             cardiac conditions, or other organ dysfunctions.&#xD;
&#xD;
          7. Signed informed consent prior to the start of any study specific procedures.&#xD;
&#xD;
          8. Women of child-bearing potential must have a negative serum or urine pregnancy test.&#xD;
&#xD;
          9. Male and female patients must agree to use acceptable contraceptive methods for the&#xD;
             duration of the study and for at least one month after the last drug administration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The interval from prior treatment to time of study drug administration is &lt; 2 weeks&#xD;
             for cytotoxic agents or &lt; 5 half-lives for noncytotoxic agents. Exceptions: Use of&#xD;
             hydroxyurea is allowed before the start of study and is to be discontinued prior to&#xD;
             the initiation of study treatment. At the investigator's discretion, for patients with&#xD;
             significant leukocytosis that develops during the early treatment cycles, hydroxyurea&#xD;
             may be administered. The hydroxyurea should be discontinued as soon as clinically&#xD;
             appropriate.&#xD;
&#xD;
          2. Any &gt;grade 1 persistent clinically significant toxicities from prior chemotherapy.&#xD;
&#xD;
          3. Inadequate Cardiac (left ventricular ejection fraction ≤40%) function.&#xD;
&#xD;
          4. White blood cell (WBC) count &gt;15,000/μL (Note: Patients considered for possible&#xD;
             venetoclax-containing regimen must have WBC ≤10k/μL prior to initiating venetoclax&#xD;
             treatment).&#xD;
&#xD;
          5. For patients with prior hematopoietic stem cell transplant (HSCT):&#xD;
&#xD;
               1. Less than 3 months since HSCT&#xD;
&#xD;
               2. Acute Graft versus Host Disease (GvHD) &gt;Grade 1&#xD;
&#xD;
               3. Chronic GvHD &gt;Grade 1&#xD;
&#xD;
          6. Any concomitant condition that in the opinion of the investigator could compromise the&#xD;
             objectives of this study and the patient's compliance.&#xD;
&#xD;
          7. A pregnant or lactating woman.&#xD;
&#xD;
          8. Current malignancies of another type. Exceptions: Patients may participate if they&#xD;
             have previously treated and currently controlled prostate cancer, or adequately&#xD;
             treated in situ cervical cancer or basal cell skin cancer, or other malignancies with&#xD;
             no evidence of disease for 2 years or more.&#xD;
&#xD;
          9. Patient has acute promyelocytic leukemia (APL).&#xD;
&#xD;
         10. Patients with known HIV, active HBV or active HCV infection (note: testing for these&#xD;
             infections is not required). For patients with evidence of chronic hepatitis B virus&#xD;
             (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if&#xD;
             indicated. Patients with a history of hepatitis C virus (HCV) infection must have been&#xD;
             treated and cured. For patients with HCV infection who are currently on treatment,&#xD;
             they are eligible if they have an undetectable HCV viral load.&#xD;
&#xD;
         11. Documented or known clinically significant bleeding disorder.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tapan Kadia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tapan Kadia, MD</last_name>
    <phone>713-792-7026</phone>
    <email>tkadia@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>O'Neal Comprehensive Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mary L Jerome, RN, BSN</last_name>
      <phone>205-934-5092</phone>
      <email>msjerome@uab.edu</email>
    </contact>
    <investigator>
      <last_name>Sravanti Ranagaraju, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Banner MD Anderson</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Winkle, RN, BSN</last_name>
      <phone>480-256-3421</phone>
    </contact>
    <investigator>
      <last_name>Rajneesh Nath, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HonorHealth (VGPCC Cancer Transplant Institute)</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mei Yu</last_name>
      <phone>480-323-7335</phone>
      <email>myu@honorhealth.com</email>
    </contact>
    <investigator>
      <last_name>Veena Fauble, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724-5024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Chu</last_name>
      <phone>520-626-1183</phone>
      <email>chum@email.arizona.edu</email>
    </contact>
    <investigator>
      <last_name>Sharad Khurana, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>An To</last_name>
      <email>aqto@uci.edu</email>
    </contact>
    <investigator>
      <last_name>Deepa Jeyakumar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruck Habtemariam</last_name>
      <phone>310-794-0242</phone>
      <email>bhabtemariam@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Gary Schiller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UF-Health Cancer Center Gainesville</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christina Cline, RN, BSN, CCRC</last_name>
      <phone>352-273-6840</phone>
      <email>clcline@ufl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Zeina Al-Mansour, MD</last_name>
      <email>Zeina.Al-Mansour@medicine.ufl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Zeina Al-Mansour, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baptist MD Anderson</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol Fairchild</last_name>
      <phone>419-320-3298</phone>
      <email>Carol.Fairchild@bmcjax.com</email>
    </contact>
    <investigator>
      <last_name>William Hammond, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UF-Health Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tarra R. Ullig, NCMA, CCRC</last_name>
      <phone>904-244-1103</phone>
      <email>tarra.ullig@jax.ufl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Walter Quan, MD</last_name>
      <phone>904-244-1680</phone>
      <email>Walter.Quan@jax.ufl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Walter Quan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AdventHealth Medical Group Blood and Marrow Transplant at Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felipe Valerio</last_name>
      <phone>321-460-3580</phone>
      <email>Felipe.Valerio@AdventHealth.com</email>
    </contact>
    <investigator>
      <last_name>Rashang Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgia Cancer Center at Augusta University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Jenkins</last_name>
      <phone>706-721-1206</phone>
      <email>kejenkins@augusta.edu</email>
    </contact>
    <investigator>
      <last_name>Jorge Cortes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Yecke</last_name>
      <phone>312-942-5798</phone>
      <email>Angela_Yecke@rush.edu</email>
    </contact>
    <investigator>
      <last_name>Melissa Larson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Decatur Memorial Hospital-Cancer Care Specialists of Central IL</name>
      <address>
        <city>Decatur</city>
        <state>Illinois</state>
        <zip>62526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dianna Richardson</last_name>
      <phone>217-876-4760</phone>
      <email>richardson.dianna@mhsil.com</email>
    </contact>
    <investigator>
      <last_name>James Wade, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Hines</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Martin, RN, BSN</last_name>
      <phone>708-327-3095</phone>
      <email>smartin19@luc.edu</email>
    </contact>
    <investigator>
      <last_name>Stephanie Tsai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Franciscan Health Indianapolis</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melanie Coleman</last_name>
      <phone>317-528-7298</phone>
      <email>Melanie.Coleman@franciscanalliance.org</email>
    </contact>
    <investigator>
      <last_name>Luke Akard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Kansas Cancer Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ken Byrd, MD</last_name>
      <email>Kbyrd3@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Ken Byrd, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of KY- Markey Cancer Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gerhard Hildebrandt, MD</last_name>
      <email>Gerhard.hildebrandt@uky.edu</email>
    </contact>
    <investigator>
      <last_name>Gerhard Hildebrandt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40241</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Ochsner Benson Cancer Center</name>
      <address>
        <city>Jefferson</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Forschler</last_name>
      <phone>504-842-3918</phone>
      <email>melissa.forschler@ochsner.org</email>
    </contact>
    <contact_backup>
      <last_name>Elise Curry</last_name>
      <phone>504-842-8084</phone>
      <email>elisemarie.curry@ochsner.org</email>
    </contact_backup>
    <investigator>
      <last_name>Laura Finn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tulane University</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elise Tatje</last_name>
      <phone>504-988-2987</phone>
      <email>etatje@tulane.edu</email>
    </contact>
    <investigator>
      <last_name>Hana Safah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise Campbell</last_name>
      <phone>313-916-2438</phone>
      <email>dcampb12@hfhs.org</email>
    </contact>
    <contact_backup>
      <last_name>Karen Leszczynski</last_name>
      <phone>313-916-3590</phone>
      <email>Kleszcz2@hfhs.org</email>
    </contact_backup>
    <investigator>
      <last_name>Philip Kuriakose, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elizabeth Sherriff</last_name>
      <phone>601-984-1962</phone>
      <email>esherriff@umc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Stephanie Elkins, MD</last_name>
      <email>selkins@umc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Stephanie Elkins, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York Medical College</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyaw Swa</last_name>
      <phone>914-493-8375</phone>
      <email>kswa@nymc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Paul Baskind</last_name>
      <phone>914-493-8375</phone>
      <email>paul_baskind@nymc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Karen Seiter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novant Health Cancer Institute - Elizabeth (Hematology)</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrea Marrs</last_name>
      <phone>980-302-6600</phone>
      <email>asmarrs@novanthealth.org</email>
    </contact>
    <investigator>
      <last_name>Patricia Kropf, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>East Carolina University</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Denise Brigham</last_name>
      <phone>252-744-4924</phone>
      <email>Brighamd16@ecu.edu</email>
    </contact>
    <investigator>
      <last_name>Darla Liles, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vidant Oncology</name>
      <address>
        <city>Kinston</city>
        <state>North Carolina</state>
        <zip>28501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JoAnne Moye</last_name>
      <phone>252-559-2201</phone>
      <email>Joanne.moye@vidanthealth.com</email>
    </contact>
    <investigator>
      <last_name>Misbah Qadir</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novant Health Cancer Institute - Forsyth (Hematology)</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Marrs</last_name>
      <phone>336-718-5570</phone>
      <email>asmarrs@novanthealth.org</email>
    </contact>
    <investigator>
      <last_name>James Dugan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Comprehensive Cancer Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brittany Choi, RN</last_name>
      <phone>336-713-6928</phone>
      <email>bmabe@wakehealth.edu</email>
    </contact>
    <contact_backup>
      <last_name>Rebecca Dellinger-Johnson</last_name>
      <phone>3367137035</phone>
      <email>radellin@wakehealth.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Timothy Pardee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carrie Smith</last_name>
      <email>csmith@gabrailcancercenter.com</email>
    </contact>
    <investigator>
      <last_name>Nashat Gabrail, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Cancer Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Harris</last_name>
      <phone>513-584-8216</phone>
      <email>harria4@ucmail.uc.edu</email>
    </contact>
    <investigator>
      <last_name>Emily Curran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seidman Cancer Center, University Hospitals, Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol Tackett</last_name>
      <phone>216-844-5715</phone>
      <email>carol.tackett@uhhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Brenda Cooper, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prisma Health Cancer Institute</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanne Hetzel</last_name>
      <email>joanne.hetzel@prismahealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Salazar</last_name>
      <email>Jennifer.Salazar@PrismaHealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Elizabeth Cull, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Avera Medical Group</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Donelan</last_name>
      <phone>605-322-3090</phone>
      <email>lauren.brandt@avera.org</email>
    </contact>
    <investigator>
      <last_name>Roberto Ferro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Zuckerman</last_name>
      <phone>214-648-5567</phone>
      <email>Julie.zuckerman@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Prapti Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Glenn Wilson, RN</last_name>
      <email>ggwilson@bcm.edu</email>
    </contact>
    <investigator>
      <last_name>Gustavo A Rivero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kiran Naqvi, MD</last_name>
      <phone>713-745-5073</phone>
      <email>knaqvi@mdanderson.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Vermont Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane Walsh</last_name>
      <phone>802-656-9926</phone>
      <email>Jane.e.walsh@uvm.edu</email>
    </contact>
    <investigator>
      <last_name>Diego Adrianzen-Herrera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cory Caldwell</last_name>
      <phone>434-297-4182</phone>
      <email>CJC2P@virginia.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Keng, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Multicare Institute for Research and Innovation</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Horton</last_name>
      <phone>509-768-3099</phone>
      <email>jkhorton@multicare.org</email>
    </contact>
    <investigator>
      <last_name>Brett Gourley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 11, 2019</study_first_submitted>
  <study_first_submitted_qc>April 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2019</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Decitabine</mesh_term>
    <mesh_term>Venetoclax</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
    <mesh_term>Cladribine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

